Nasdaq Stays BioAtla Delisting and Trading Suspension Pending Review

summarizeSummary

BioAtla announced that Nasdaq has stayed its delisting and trading suspension, allowing the company's common stock to continue trading during a review process that could last several months.

check_boxKey Events

• Delisting Stayed

  Nasdaq's Listing Council has called for a review of the delisting determination issued on February 6, 2026, and has stayed the suspension of trading and delisting action.

• Continued Trading

  BioAtla's common stock will continue to trade on Nasdaq during the Listing Council's review process, which may take several weeks to a few months to complete.

• Appeal Initiated

  The company requested an immediate review and stay, arguing that Nasdaq's actions regarding compliance consideration and super-voting stock policy caused irreparable harm.

• Uncertainty Remains

  There is no assurance that the Listing Council's review will result in the continued listing of the company's common stock on Nasdaq.

auto_awesomeAnalysis

This filing provides a critical, albeit temporary, reprieve for BioAtla, following the formal delisting determination announced on February 6, 2026. The Nasdaq Listing and Hearing Review Council's decision to stay the suspension and delisting means the company's stock will continue to trade, preventing immediate liquidity issues for investors. While this grants BioAtla more time to address its non-compliance with Nasdaq's bid price and stockholders' equity requirements, the ultimate outcome of the review process remains uncertain. Investors should monitor the progress of this review closely, as the company still faces significant delisting risk.